Patents by Inventor Cindy Q. Yao

Cindy Q. Yao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Gene signature of residual risk following endocrine treatment in early breast cancer
    Patent number: 11566292
    Abstract: There is described herein a method of prognosing endocrine-only treatment in a subject with breast cancer, the method comprising: a) providing a tumor sample of the breast cancer; b) determining the expression level of at least 40 of the genes listed in Table 4 in the tumor sample; c) comparing said expression levels to a reference expression level of the group of genes from control samples from a cohort of subjects; and d) determining the residual risk associated with the breast cancer; wherein a statistically significant difference or similarity in the expression of the group of genes compared to the reference expression level corresponds to a residual risk associated with breast cancer.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: January 31, 2023
    Assignee: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)
    Inventors: Jane Bayani, John M. S. Bartlett, Cindy Q. Yao, Paul C. Boutros
  • Gene Signature of Residual Risk Following Endocrine Treatment in Early Breast Cancer
    Publication number: 20190010553
    Abstract: There is described herein a method of prognosing endocrine-only treatment in a subject with breast cancer, the method comprising: a) providing a tumor sample of the breast cancer; b) determining the expression level of at least 40 of the genes listed in Table 4 in the tumor sample; c) comparing said expression levels to a reference expression level of the group of genes from control samples from a cohort of subjects; and d) determining the residual risk associated with the breast cancer; wherein a statistically significant difference or similarity in the expression of the group of genes compared to the reference expression level corresponds to a residual risk associated with breast cancer.
    Type: Application
    Filed: December 7, 2016
    Publication date: January 10, 2019
    Inventors: Jane Bayani, John M.S. Bartlett, Cindy Q. Yao, Paul C. Boutros